INTRODUCTION {#s1}
============

Immune co-stimulatory and co-inhibitory receptors determined the functional outcome of T cell receptor (TCR) signaling and immune surveillance \[[@R1]\]. Tumors can modulate the interactions between inhibitory receptors and ligands to scape immune responses \[[@R2], [@R3]\]. For example, the co-inhibitory receptor programmed cell death 1 (PD-1) plays a key role in cancer immune, especially in the immune escape phase \[[@R4]\]. PD-1 can be expressed in activated CD4 + and CD8 + T cells, but also in some natural killer cells and B cells \[[@R5]\]. When PD-1 binds to the ligand PD-L1 (B7-H1) expressed on the surface of tumors, it strongly inhibits the production of T cells and cytokines \[[@R6], [@R7]\], promoting tumor cell growth and immune escape \[[@R8], [@R9]\].

PD-L1 also plays a key role in binding to PD-1 receptors expressed on activated T cells in T cell co-suppression and depletion \[[@R9]--[@R11]\]. PD-L1 expressed on tumor cells promotes tumor cell-specific T cell inactivation or apoptosis, leading to tumor cell growth and exacerbation of tumor immune escape \[[@R12]\]. PD-L1 is expressed in many types of human cancers, including in esophageal, gastrointestinal, pancreatic, breast, lung and kidney cancers \[[@R10]--[@R14]\]. Clinical trials suggest that blocking the PD-1/PD-L1 interaction using anti-PD-1 antibodies can be effective against several different malignancies, including melanoma, lung cancer, kidney cancer and bladder cancer \[[@R15]--[@R19]\].

In addition to serving as a therapeutic target, PD-L1 may also be useful as a prognostic biomarker \[[@R22]\]. However, whether PD-L1 expression is associated with worse prognosis for patients with primary solid tumors remains controversial \[[@R20]--[@R22]\]. Therefore we meta-analyzed all available evidence to address this question comprehensively.

RESULTS {#s2}
=======

A total of 1,258 records were retrieved from PUBMED, EMBASE, Web of Science and EBSCO (Figure [1](#F1){ref-type="fig"}). After excluding 825 duplicate publications, we reviewed the abstracts and titles of the remaining 433 articles. This led to the exclusion of another 288 records that were not original research articles published in English. The remaining articles were read in full, leading to the exclusion of 86 records because they did not deal with human patients or solid tumors, or because they failed to report adequate outcomes data. In the end, 59 articles were included in the meta-analysis.

![Flow chart of study selection](oncotarget-09-5058-g001){#F1}

Key features of the 59 studies are summarized in Table [1](#T1){ref-type="table"}; 35 studies involved Asian populations and 24 involved non-Asian populations. The studies analyzed 20,004 patients from China \[[@R23]--[@R41]\], France \[[@R42]\], New Zealand \[[@R43], [@R44]\], Brazil \[[@R45]\], Australia \[[@R46]\], Canada \[[@R47], [@R48]\], Italy \[[@R49]\], Germany \[[@R50], [@R51]\], United States \[[@R52]--[@R65]\], Japan \[[@R66]--[@R74]\], South Korea \[[@R75]--[@R78]\], Switzerland \[[@R79]\] and Taiwan \[[@R80], [@R81]\]. PD-L1 expression, which was analyzed in similar ways across all studies, was characterized as positive in 6,028 patients and negative in the remaining 13,976. One third of the studies (19) involved gastrointestinal tumors, while the remaining 40 involved other types of tumors. Altogether 11 malignancies were represented in the patient population: breast cancer (5 studies), renal cell carcinoma (7), colorectal cancer (3), esophageal cancer (3), gastric cancer (7), hepatocellular carcinoma (7), Merkel cell carcinoma (3), small cell lung cancer (11), oral squamous cell carcinoma (5), pancreatic cancer (3), and urinary tract epithelial cell carcinoma (4).

###### Characteristics of studies included in the meta-analysis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                 Country       Tumor type                                Characteristic   Age                Gender\         No. patients positive/ negative for PD-L1   PD-L1-positive OS (%)   PD-L1-negative OS (%)   *P*                     
                                                                                                                    male / female                                                                                                                       
  --------------------- ------------- ----------------------------------------- ---------------- ------------------ --------------- ------------------------------------------- ----------------------- ----------------------- ----- ----- ----- ----- ---------
  **Qin 2015**          China         Breast cancer                             Primary          47(21-84)          \-              189/681                                     100                     85                      81    100   98    92    \<0.001

  **Sabatier 2015**     France        Breast cancer                             Primary          ≤50: 1288\         \-              1076/4378                                   97                      90                      82    97    90    81    0.070
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>50: 3207                                                                                                                                             

  **Muenst 2014**       Switzerland   Breast cancer                             Primary          63.8 ± 14.2        \-              152/498                                     90                      55                      37    98    85    80    \<0.001

  **Baptista 2016**     Brazil        Breast cancer                             Primary          ≤50: 176\                          107/82                                      98                      90                      85    100   96    93    0.030
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>50: 204                                                                                                                                              

  **Beckers 2016**      Australia     Breast cancer                             Primary          \-                 \-              123/38                                      96                      92                      81    96    73    65    0.035

  **Droeser 2013**      Italy         Colorectal cancer                         Primary          69.9 (30--96)      741/673         669/1420                                    84                      71                      61    72    48    37    \<0.001

  **Shi SJ 2013**       China         Colorectal cancer                         Primary          59.8 ± 12.5        91/116          64/143                                      75                      54                      42    90    72    61    0.017

  **Zhu 2014**          China         Colorectal cancer                         Primary          ≤50: 54\           53/48           55/46                                       \-                      \-                      62    \-    \-    80    0.051
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>50: 47                                                                                                                                               

  **Krambeck 2007**     USA           Renal cell carcinoma                      Primary          ≤65: 54\           150/148         70/228                                      78                      62                      48    91    83    76    \<0.005
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>65: 47                                                                                                                                               

  **Thompson 2005**     Canada        Renal cell carcinoma                      Primary          \-                 \-              103/196                                     84                      67                      52    93    87    84    \<0.001

  **Thompson 2007**     Canada        Renal cell carcinoma                      Primary          ≤65: 138\          177/90          142/267                                     88                      68                      \-    94    85    \-    0.004
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>65: 129                                                                                                                                              

  **Abbas 2016**        Germany       Renal cell carcinoma                      Primary          63 (31--88)        116/61          37/140                                      85                      57                      47    92    75    66    0.005

  **Choueiri 2014**     USA           Renal cell carcinoma                      Primary          59 (24--81)        55/46           11/90                                       72                      48                      48    98    95    85    \<0.001

  **Thompson 2004**     USA           Renal cell carcinoma                      Primary          \-                 \-              87/109                                      87                      62                      \-    95    92    \-    \<0.001

  **Thompson 2006**     USA           Renal cell carcinoma                      Primary          \-                 \-              73/233                                      78                      51                      42    95    90    83    \<0.001

  **Ohigashi 2005**     Japan         Esophageal cancer                         Primary          ≤65: 24\           32/9            18/41                                       60                      18                      18    88    53    45    0.001
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>65: 17                                                                                                                                               

  **Tanaka 2016**       Japan         Esophageal cancer                         Primary          62.6 ± 10.0        157/33          53/127                                      61                      30                      25    79    56    51    0.001

  **Chen 2014**         China         Esophageal cancer                         Primary          ≤65: 51\           76/23           79/20                                       100                     44                      17    83    44    37    0.675
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>65: 48                                                                                                                                               

  **Loos 2011**         Germany       Esophageal cancer                         Primary          \-                 \-              37/64                                       79                      51                      32    96    82    69    \<0.001

  **Shohei 2016**       Japan         Gastric carcinoma                         Primary          67 ± 14            75/30           28/105                                      84                      41                      10    91    63    51    0.022

  **Geng 2015**         China         Gastric carcinoma                         Primary          ≤65: 65\           61/39           65/100                                      72                      41                      29    87    61    37    0.026
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>65: 35                                                                                                                                               

  **Hou 2014**          China         Gastric carcinoma                         Primary          ≤58: 55\           75/36           70/111                                      78                      46                      32    93    77    68    \<0.001
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>58: 56                                                                                                                                               

  **Wu 2006**           Sweden        Gastric carcinoma                         Primary          ≤65: 64\           75/27           43/102                                      75                      38                      30    98    71    64    0.001
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>65: 38                                                                                                                                               

  **Tamura 2015**       Japan         Gastric carcinoma                         Primary          66.1 (17-89)       305/126         128/303                                     90                      65                      49    94    78    64    0.001

  **Zheng 2014**        China         Gastric carcinoma                         Primary          ≤60: 42\           62/18           33/47                                       86                      65                      52    91    69    53    0.636
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>60: 38                                                                                                                                               

  **Qing 2015**         USA           Gastric carcinoma                         Primary          ≤60: 42\           72/35           54/107                                      81                      28                      18    93    47    27    0.004
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>60: 38                                                                                                                                               

  **Gao 2009**          China         Hepatocellular carcinoma                  Primary          52 (18-81)         204/36          60/180                                      70                      42                      39    83    57    49    0.029

  **Jung 2016**         South Korea   Hepatocellular carcinoma                  Primary          ≤53: 44\           69/16           23/62                                       43                      19                      17    90    69    59    \<0.001
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>53: 41                                                                                                                                               

  **Kan 2015**          China         Hepatocellular carcinoma                  Primary          ≤50: 56\           108/20          105/23                                      30                      5                       0     50    15    10    0.001
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>50: 72                                                                                                                                               

  **Umemoto 2015**      Japan         Hepatocellular carcinoma                  Primary          64 ± 10            71/9            37/43                                       74                      51                      40    80    73    71    0.051

  **Zeng 2011**         China         Hepatocellular carcinoma                  Primary          53.1(35--68        109/32          31/32                                       38                      \-                      \-    85    \-    \-    0.000

  **Gabrielson 2016**   USA           Hepatocellular carcinoma                  Primary          61 (30--86)        50/15           30/35                                       85                      85                      \-    53    45    \-    0.029

  **Wu 2009**           China         Hepatocellular carcinoma                  Primary          48, 23--75         65/6            35/36                                       81                      54                      40    97    83    71    0.014

  **Azuma 2014**        Japan         Lung cancer                               Primary          66 (39-82)         91/73           82/164                                      \-                      \-                      38    \-    \-    56    0.039

  **Chen 2012**         China         Lung cancer                               Primary          ≤54: 23\           26/14           69/120                                      71                      11                      \-    85    48    \-    \<0.001
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>54: 17                                                                                                                                               

  **Cooper 2015**       USA           Lung cancer                               Primary          \-                 477/201         628/678                                     95                      73                      62    84    54    44    0.023

  **Jiang 2015**        China         Lung cancer                               Primary          ≤60: 15\           39/40           50/79                                       100                     91                      84    83    74    70    0.042
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>60: 64                                                                                                                                               

  **Kim 2015**          South Korea   Lung cancer                               Primary          65 (45--81)        33/8            89/331                                      65                      38                      27    78    49    49    0.570

  **Mu 2011**           China         Lung cancer                               Primary          \-                 \-              58/109                                      87                      20                      \-    95    38    \-    \<0.005

  **Velcheti 2014**     USA           Lung cancer                               Primary          ≤70: 232\          260/37          56/155                                      78                      43                      27    87    61    51    0.028
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>70: 80                                                                                                                                               

  **Yang 2014**         Taiwan        Lung cancer                               Primary          ≤70: 132\          54/109          65/163                                      98                      93                      91    98    87    83    0.027
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>70: 31                                                                                                                                               

  **Zhang 2014**        China         Lung cancer                               Primary          ≤58: 73\           84/59           70/143                                      84                      71                      53    97    89    77    0.002
                                                                                                 1021 (28%)\                                                                                                                                            
                                                                                                 267 (31%)\                                                                                                                                             
                                                                                                 \>58: 70                                                                                                                                               

  **Song 2016**         China         Lung cancer                               Primary          \<60: 207\         198/187         186/199                                     99                      71                      40    99    79    52    0.069
                                                                                                 ≥60: 178                                                                                                                                               

  **Inamura 2016**      Japan         Lung cancer                               Primary          \<60: 96\          142/126         43/225                                      85                      69                      55    95    81    71    0.019
                                                                                                 ≥60: 172                                                                                                                                               

  **Chen 2009**         China         Pancreatic cancer                         Primary          \<60: 61\          76/23           18/40                                       32                      8                       \-    84    58    17    0.001
                                                                                                 ≥60: 55                                                                                                                                                

  **Nomi 2007**         Japan         Pancreatic cancer                         Primary          \-                 \-              20/51                                       48                      12                      \-    78    24    \-    0.016

  **Wang 2010**         China         Pancreatic cancer                         Primary          \-                 40/10           23/40                                       87                      8                       \-    100   33    \-    \<0.001

  **Gadiot 2011**       Netherlands   Merkel cell carcinoma                     Primary          \-                 36/27           16/63                                       \-                      51                      37    \-    68    52    0.200

  **Hino 2010**         Japan         Merkel cell carcinoma                     Primary          68.84 ± 2.85       38/21           34/59                                       \-                      \-                      52    \-    \-    81    0.040

  **Taube 2012**        USA           Merkel cell carcinoma                     Primary          \-                 76/74           57/150                                      \-                      \-                      84    \-    \-    61    0.330

  **Boorjian 2008**     USA           Urinary tract epithelial cell carcinoma   Primary          \-                 259/59          39/314                                      58                      51                      43    91    82    67    0.005

  **Nakanishi 2006**    Japan         Urinary tract epithelial cell carcinoma   Primary          \-                 47/18           46/65                                       86                      68                      57    100   100   100   0.021

  **Wang 2009**         China         Urinary tract epithelial cell carcinoma   Primary          \-                 31/5            36/50                                       91                      68                      \-    100   100   \-    0.020

  **Xylinas 2014**      USA           Urinary tract epithelial cell carcinoma   Primary          65.9 (60.5e72.2)   244/58          76/226                                      83                      66                      63    95    82    69    0.020

  **Kim 2016**          South Korea   Oral squamous cell cancer                 Primary          65 (45--81)        33/8            90/43                                       97                      83                      80    98    83    75    0.625

  **Lin 2015**          Taiwan        Oral squamous cell cancer                 Primary          \<56: 162\         236/69          133/172                                     81                      62                      56    81    62    58    0.225
                                                                                                 ≥56: 143                                                                                                                                               

  **Cho 2011**          South Korea   Oral squamous cell cancer                 Primary          \<59: 20\          32/13           26/45                                       72                      51                      43    72    63    63    0.012
                                                                                                 ≥59: 25                                                                                                                                                

  **Oliveira 2015**     USA           Oral squamous cell cancer                 Primary          \<60: 62\          85/11           47/96                                       81                      47                      \-    61    18    \-    0.044
                                                                                                 ≥60: 34                                                                                                                                                

  **Ukpo 2013**         USA           Oral squamous cell cancer                 Primary          55.8 ± 9.4         186/23          84/181                                      89                      74                      62    97    76    64    0.730
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PD-L1 expression and OS across all studies {#s2_1}
------------------------------------------

Meta-analysis of data from all 59 studies showed that the median OS rate was significantly lower in PD-L1-positive patients than in PD-L1-negative patients at 1 year (P = 0.039), 3 years (P \< 0.001) and 5 years (P \< 0.001; Figure [2](#F2){ref-type="fig"}). The RR for OS at the three time points (and associated 95% confidence intervals \[CIs\]) were 2.02 (1.56-2.60), 1.57 (1.34-1.83) and 1.43 (1.24-1.64) (Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

![Scatter plot of OS at 1, 3 and 5 years for patients positive or negative for PD-L1 expression\
Data come from the entire patient population.](oncotarget-09-5058-g002){#F2}

###### Meta-analysis of possible associations between PD-L1 expression and overall survival in patients with solid tumors

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group or subgroup                         N    PD-L1(+/-)   1 year OS               3 year OS   5 year OS                                                                          
  ----------------------------------------- ---- ------------ ----------------------- ----------- ----------- ---------------------- --------- ---- ---------------------- --------- ----
  **All studies**                           59   6028/13976   2.02 (1.56-2.60)        \<0.001     84          1.57 (1.34-1.83)       \<0.001   91   1.43 (1.24-1.64)       \<0.001   92

  **Ethnic subgroups**                                                                                                                                                               

  Asian                                     35   2211/4126    1.83 (1.61-2.08)^\*^    \<0.001     49          1.57 (1.39-1.77)       \<0.001   74   1.44 (1.31-1.58)       \<0.001   92

  Non-Asian                                 24   3817/9850    1.98 (1.27-3.09)        0.003       90          1.60\                  0.003     95   1.39\                  0.009     95
                                                                                                              (1.18-2.17)                           (1.08-1.78)                      

  **Tumor origin**                                                                                                                                                                   

  Gastrointestinal tumors                   24   1778/3206    2.12\                   \<0.001     86          1.52 (1.23-1.89)       \<0.001   91   1.40 (1.17-1.67)       \<0.001   91
                                                              (1.45-3.09)                                                                                                            

  Other tumors                              35   4250/10770   1.79 (1.33-2.40)        \<0.001     86          1.61 (1.30-1.98)       \<0.001   92   1.47 (1.23-1.75)       \<0.001   91

  **Tumor type**                                                                                                                                                                     

  Breast cancer                             5    1647/5677    1.80 (0.60-5.42)        0.30        79          1.79 (0.77-4.19)       \<0.18    95   1.80 (0.68-4.73)       \<0.24    96

  Esophageal cancer                         4    187/252      1.90 (0.69-5.21)        0.21        70          2.77 (1.78-4.30)^\*^   \<0.001   48   3.55 (2.63-5.65)^\*^   \<0.001   0

  Gastric carcinoma                         7    421/875      2.48 (1.80-3.41)^\*^    \<0.001     18          1.63\                  \<0.001   32   1.45\                  \<0.001   79
                                                                                                              (1.43-1.87)^\*^                       (1.18-1.79)                      

  Hepatocellular carcinoma                  7    321/339      1.87\                   0.04        78          1.40 (0.92-2.15)       0.12      84   1.58\                  0.01      83
                                                              (1.01-3.46)                                                                           (1.11-2.25)                      

  Lung cancer                               11   1396/2366    1.39 (0.69-2.81)        0.36        88          1.17 (0.84-1.63)       0.35      92   1.16 (0.86-1.57)       0.32      93

  Pancreatic cancer                         3    61/131       3.43 (2.06-5.73)^\*^    \<0.001     15          1.48 (1.06-2.06)^\*^   0.02      0    \-                     \-        \-

  Merkel cell carcinoma                     3    107/272      \-                      \-          \-          \-                     \-        \-   1.01 (0.41-2.99)       0.85      89

  urinary tract epithelial cell carcinoma   4    197/655      6.24 (3.62-10.74)^\*^   \<0.001     0           3.43 (1.50-7.84)       0.003     75   1.79 (0.86-3.70)       0.12      82

  Oral squamous cell cancer                 5    380/537      1.05 (0.58-1.93)        0.87        63          0.95 (0.72-1.26)       0.72      55   1.07 (0.89-1.29)^\*^   0.45      0

  Renal cell carcinoma                      7    208/572      3.38\                   \<0.001     24          4.14 (2.07-8.26)       \<0.001   81   2.57\                  \<0.001   79
                                                              (2.13-5.39)^\*^                                                                       (1.46-4.52)                      

  Colorectal cancer                         3    788/1609     1.17 (0.27-5.06)        0.84        95          0.94 (0.33-2. 67)      0.90      96   1.16 (0.55-2.45)       0.69      95
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N, number of studies; OS, overall survival; RR, risk ratio; 95% CI, 95% confidence interval

^\*^ These meta-analyses were performed using a fixed-effects model. All other meta-analyses were performed using a random-effects model.

Subgroup analysis by tumor type {#s2_2}
-------------------------------

Given the significant heterogeneity in the meta-analysis involving all 59 studies, we performed a series of subgroup analyses to eamine the possible correlation between PD-L1 expression and OS. PD-L1 expression was associated with worse 1-year OS for the following types of solid tumor (Table [2](#T2){ref-type="table"}): gastric cancer, 2.48 (1.80-3.41); renal cell carcinoma, 3.38 (2.13-5.39); and hepatocellular carcinoma, 1.87 (1.01-3.46). PD-L1 expression was associated with worse 3-year OS for the following cancers: esophageal cancer, 2.77 (1.78-4.30); gastric cancer, 1.63 (1.43-1.87); pancreatic cancer, 1.48 (1.06-2.06); and renal cell carcinoma, 4.14 (2.07-8.26). PD-L1 expression was associated with worse 5-year OS for esophageal cancer, 3.55 (2.63-5.65); gastric cancer, 1.45 (1.18-1.79); hepatocellular carcinoma, 1.58 (1.11-2.25); and renal cell carcinoma, 2.57 (1.46-4.52).

Among the subset of 4,984 patients with gastrointestinal tumors, 1,778 (35.6%) were PD-L1-positive and 3,206 (64.4%) were PD-L1-negative. PD-L1 expression was associated with significantly worse OS at 1 year (P = 0.004), 3 years (P = 0.005), and 5 years (P = 0.002; Figures [3](#F3){ref-type="fig"} and [7](#F7){ref-type="fig"}). The corresponding RRs and 95% CIs were 2.12(1.45-3.09), 1.52 (1.23-1.89), and 1.40 (1.17-1.67) (Table [2](#T2){ref-type="table"}).

![Scatter plot of OS at 1, 3 and 5 years for patients positive or negative for PD-L1 expression\
Data come from the subset of patients with gastrointestinal tumors.](oncotarget-09-5058-g003){#F3}

![Scatter plot of OS at 1, 3 and 5 years for patients positive or negative for PD-L1 expression\
Data come from the subset of patients with non-gastrointestinal tumors.](oncotarget-09-5058-g004){#F4}

![Scatter plot of OS at 1, 3 and 5 years for patients positive or negative for PD-L1 expression\
Data come from the subset of Asian patients.](oncotarget-09-5058-g005){#F5}

![Scatter plot of OS at 1, 3 and 5 years for patients positive or negative for PD-L1 expression\
Data come from the subset of non-Asian patients.](oncotarget-09-5058-g006){#F6}

![Forrest plot of OS at 1, 3 and 5 years for patients positive or negative for PD-L1 expression\
Data come from the subset of patients with gastrointestinal tumors.](oncotarget-09-5058-g007){#F7}

Among the subset of 4,309 patients with non-gastrointestinal tumors, 2,298 (53.3%) were PD-L1-positive and 1,404 (59.3%) were PD-L1-negative. PD-L1 expression was associated with significantly worse OS at 1 year (P = 0.017), 3 years (P = 0.010) and 5 years (P = 0.003; Figures [4](#F4){ref-type="fig"} and [8](#F8){ref-type="fig"}). The corresponding RRs and 95% CIs were 1.79 (1.33-2.40), 1.61 (1.30-1.98), and 1.47 (1.23-1.75) (Table [2](#T2){ref-type="table"}).

![Forrest plot of OS at 1, 3 and 5 years for patients positive or negative for PD-L1 expression\
Data come from the subset of patients with non-gastrointestinal tumors.](oncotarget-09-5058-g008){#F8}

Subgroup analysis by patient ethnicity {#s2_3}
--------------------------------------

Among the subset of 6,337 Asian patients, 2,211 were PD-L1-positive and 4,126 were PD-L1-negative. PD-L1 expression was associated with significantly lower OS at 1 year (P = 0.030), 3 years (P = 0.005) and 5 years (P = 0.005; Figures [5](#F5){ref-type="fig"} and [9](#F9){ref-type="fig"}). The corresponding RRs and 95% CIs were 1.86 (1.61-2.08), 1.57 (1.39-1.77), and 1.44 (1.31-1.58) (Table [2](#T2){ref-type="table"}).

![Forrest plot of OS at 1, 3 and 5 years for patients positive or negative for PD-L1 expression\
Data come from the subset of Asian patients.](oncotarget-09-5058-g009){#F9}

Among the subset of 13,667 non-Asian patients, 3,817 were PD-L1-positive and 9,850 were PD-L1-negative. PD-L1 expression was associated with significantly lower OS at 1 year (P = 0.048), 3 years (P = 0.040) and 5 years (P = 0.024; Figures [6](#F6){ref-type="fig"} and [10](#F10){ref-type="fig"}). The corresponding RRs and 95% CIs were 1.98 (1.27-3.09), 1.60 (1.18-2.17), and 1.39 (1.08-1.78) (Table [2](#T2){ref-type="table"}).

![Forrest plot of OS at 1, 3 and 5 years for patients positive or negative for PD-L1 expression\
Data come from the subset of non-Asian patients.](oncotarget-09-5058-g010){#F10}

DISCUSSION {#s3}
==========

While studies published more than a decade ago established that PD-L1 promotes cancer immune escape \[[@R82], [@R83]\] and that blocking PD-L1 can improve the anti-tumor efficacy of anti-tumor responses \[[@R84]--[@R86]\], whether PD-L1 expression by solid tumors negatively affects patient prognosis remains unclear. Here we reviewed 59 studies involving 20,004 patients with 11 types of solid tumors and found strong evidence that PD-L1 expression is associated with significantly lower OS at 1, 3 and 5 years. This effect was observed in meta-analyses involving all patients as well as several subgroups of patients stratified by ethnicity and tumor type.

PD-L1 positive expression is associated with viral infection and chronic inflammation \[[@R87]\]. Expression of PD-L1 and/or PD-1 has been described for numerous types of cancers associated with viral infection \[[@R88]\], including polycyclic virus-associated Merkel cell carcinoma \[[@R89]\], hepatitis B virus-associated hepatocellular carcinoma \[[@R33]\], human papillomavirus-associated head and neck cancer, and Epstein-Barr virus-related nasopharyngeal carcinoma \[[@R90]\]. In patients with hepatocellular carcinoma, PD-L1 expression was significantly higher in tumor macrophages than in matched normal tissues, and expression correlated with tumor grade \[[@R25]\].

Our results are consistent with previous reports that PD-L1 expression is associated with worse 5-year outcome in patients with gastrointestinal carcinomas such as esophageal cancer and gastric cancer \[[@R70], [@R79]\] as well as colorectal cancer \[[@R25]\]. The precise mechanisms whereby PD-L1 expression may worsen prognosis are unknown; When PD-1 binds to the ligand PD-L1 (B7-H1) expressed on the surface of tumors, PD-1 has been shown to promote tumor cell-specific T cell inactivation or apoptosis \[[@R12]\].

The results of this meta-analysis should be interpreted cautiously because of several limitations. One is the lack of a standardized assay and cut-off value for classifying patients as PD-L1-positive. This may help explain the high heterogeneity observed across the included studies. Another limitation is our exclusion of gray literature, which may have increased the risk of publication bias and selection bias.

Despite these limitations, this large meta-analysis provides strong evidence that expression of PD-L1 may be a meaningful index for predicting prognosis in a wide variety of patients with solid tumors. These findings justify more focused prognostic studies in well-defined patient populations in which a panel of clinically relevant outcomes beyond only OS are considered.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

PubMed, EMBASE, Web of Science and EBSCO were searched through 15 January 2017 to identify cohort and case-control studies examining the relationship between PD-L1 expression and prognosis of patients with solid tumors. The following search terms were used: *programmed death-ligand 1, PD-L1, B7-H1, CD274* and *solid tumor*.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

To be included in our meta-analysis, studies had to involve (1) primary solid tumors in human patients; (2) The main content of the articles is to analyze the relationship between the expression of PD-L1 and the prognosis of solid tumors in patients; (3) a hospital-based or population-based case-control or cohort design, regardless of sample size; (4) immunohistochemical assay of PD-L1 expression as high and low PD-L1 expression; (5) all patients underwent surgery; and (6) adequate reporting of overall survival (OS) data. When eligible studies involved overlapping patient populations, only the most recent or complete report was included. Studies were excluded if they were letter, summary of meeting and review; if they were published in a language other than English; or if they failed to report adequate data; or they investigated metastatic tumors. Gray literature (Reports and papers that were not published in PubMed, EMBASE, Web of Science and EBSCO) was not included into this study. Reference lists within identified articles were also searched manually to identify additional articles.

Meta-analysis outcomes {#s4_3}
----------------------

The primary outcome in the meta-analysis was OS. This outcome was compared between patients showing high or positive PD-L1 expression and patients showing low or no expression, as defined within the individual studies.

Data collection {#s4_4}
---------------

Two researchers (P.-C.Y, X.X) independently screened studies for inclusion. Disagreements were resolved by discussion and, when necessary, consultation with a third author (S.Z). The first author\'s name, year of publication, country, number of patients, and tumor type were extracted from each study, and OS results for 1, 3 and 5 years were extracted from tables or Kaplan-Meier curves.

Statistical analysis {#s4_5}
--------------------

Forest plots of OS were generated using RevMan 5.3 (Cochrane Collaboration, Copenhagen, Denmark). Weighted risk ratio (RR) estimates were generated from pooled data using Mantel-Haenszel random-effects meta-analysis, unless no statistically heterogeneity, in which case fixed-effects meta-analysis was performed. Statistical heterogeneity in meta-analyses was assessed using Cochrane\'s Q and I^2^statistics. Survival results were analyzed using scatter plots generated in Prism 5 (Graphpad Software, San Diego, USA). The results for different patient groups were compared using the log-rank test. The threshold of statistical significance was defined as P \< 0.05.
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